logo
Plus   Neg
Share
Email

Informa 10-month Underlying Revenue Rises - Quick Facts

Informa plc (INFMF.PK,INF.L), an Exhibitions, Events, Business Intelligence and Academic Publishing Group, reported Monday that it has continued to perform well, with growth in revenue, adjusted profit, and earnings for the 10-month period to October 31. The full-year performance is on track.

In its trading update, the company said its underlying revenue growth was at 2.8%, ahead of significant, seasonally stronger November/December trading period.

Stephen Carter, Group Chief Executive, said, "After ten months trading in 2019, despite an unpredictable economic/geo-political backdrop, the enlarged Informa Group continues to demonstrate resilience and performance, remaining on track for a sixth consecutive year of growth in underlying revenue, profit, adjusted earnings and cashflow."

The company noted that November and December are significant trading months for the enlarged Informa Group, representing around 20% of annual revenue. November alone is expected to account for more than 350 million pounds.

Despite ongoing economic/geo-political uncertainty, forward pacing for the remainder of 2019 provides reassurance on Group revenue guidance of 3.5% for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT